On Nov. 1, BioMarin Pharmaceutical
- Revenues beat the estimates by 11.2%, while EPS topped the consensus estimate with a loss of $0.08.
- Revenue increases were mainly due to stronger product sales, particularly in Aldurazyme and Naglazyme.
- Restrained spending and top-line growth let to a significant movement toward profitability.
- Get our full Foolish Take on BioMarin's latest quarter.
(Figures in thousands, except per-share data)
Income Statement Highlights
Avg. Est. |
Q3 2006 |
Q3 2005 |
Change |
|
---|---|---|---|---|
Sales |
$19,716 |
$24,927 |
$7,579 |
228.9% |
Net Profit* |
-- |
($7,036) |
($15,476) |
N/A |
EPS |
($0.12) |
($0.08) |
($0.21) |
N/A |
Diluted Shares |
-- |
86,269 |
71,996 |
19.8% |
Get back to basics with a look at the income statement.
Margin Checkup
Q3 2006 |
Q3 2005 |
Change* |
|
---|---|---|---|
Gross Margin |
89.52% |
97.84% |
(8.32) |
Operating Margin |
(16.51%) |
(173.82%) |
157.31 |
Net Margin |
(28.23%) |
(204.20%) |
175.97 |
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
Assets |
Q3 2006 |
Q3 2005 |
Change |
---|---|---|---|
Cash + ST Invest. |
$293.9 |
$65.9 |
346% |
Accounts Rec. |
$13.0 |
$5.3 |
145.3% |
Inventory |
$25.8 |
$7.7 |
235.1% |
Liabilities |
Q3 2006 |
Q3 2005 |
Change |
---|---|---|---|
Accounts Payable* |
$29.2 |
$22.9 |
27.5% |
Long-Term Debt |
$293.1 |
$214.4 |
36.7% |
Learn the ways of the balance sheet.
Cash Flow Highlights
A statement of cash flows was not provided.
Find out why Fools always follow the money.
Related Companies:
-
Medarex
(NASDAQ:MEDX) -
Crucell
NV
(NASDAQ:CRXL) -
Regeneron Pharmaceuticals
(NASDAQ:REGN) -
ZymoGenetics
(NASDAQ:ZGEN)
Related Foolishness:
Get the latest updates from the fast-paced world of biotech, and other spawning grounds for amazing growth stocks, with a free 30-day trial to Motley Fool Rule Breakers.
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.